AstraZeneca Advances In Early Stage Lung Cancer With Imfinzi And Tagrisso
Pursuing Leaders With Double Neoadjuvant/Adjuvant Approach
AstraZeneca’s Imfinzi is playing catch-up to other PD1/L1 targeting agents in neoadjuvant/adjuvant NSCLC with new data from AEGEAN, but new survival data for Tagrisso from ADAURA consolidate its dominance in early-stage EGFR positive disease.
